What did @dr.vassily actually say?
The creator, who identifies as Dr. Vos alongside a Cornell-affiliated MD, made a string of claims about BPC-157's cardiovascular benefits, framed around a familiar narrative: Big Pharma suppresses it because it can't be patented. Specifically, he said the peptide may "help heal your blood vessels from the inside out," supports endothelial repair, promotes angiogenesis, and could address conditions ranging from high blood pressure to erectile dysfunction and long COVID. He acknowledged the data is preclinical, which is worth noting. He also warned viewers to distrust doctors who say "there isn't enough data," calling that a deflection. That last part is where things get complicated.
The video is careful in places, using "may" and "appears to," but the practical application section drops that hedging entirely, listing specific conditions BPC-157 "could be used for" as though clinical evidence already supports those uses. It does not.
Does the science back this up?
For the rodent data, yes. For humans, there is essentially nothing published yet. The core preclinical findings are real. Studies in rats have shown BPC-157 accelerates wound healing, reduces inflammation, and does appear to influence angiogenic pathways. Sikiric et al., who have published extensively in journals like Current Pharmaceutical Design, have documented effects on endothelial function and vascular tone in animal models. The angiogenesis claim has some basis in this literature.
But here is the problem: rodent gastrointestinal and vascular physiology differs meaningfully from human physiology. The leap from "BPC-157 reduced oxidative stress markers in rats" to "BPC-157 may fix endothelial dysfunction in humans with high blood pressure" is not a small one. It requires human pharmacokinetic data, dose-response studies, and safety surveillance across populations, none of which exist in peer-reviewed form for this compound. A 2022 review in Pharmaceuticals by Gwyer et al. summarized the state of BPC-157 research plainly: promising in animal models, no completed human RCTs published.
What did they get wrong (or right)?
Credit where it is due: the creator correctly identified BPC-157 as a peptide fragment derived from gastric protein, correctly explained endothelial function and its role in cardiovascular disease, and did repeatedly flag the preclinical limitation. That transparency matters.
What is wrong, or at minimum misleading, is the patent argument. The claim that "it can't be patented and therefore won't get funded" is a popular talking point in peptide communities, but it is an oversimplification. NIH and academic institutions fund research on non-patentable compounds regularly. Metformin is a prime example. The actual reason BPC-157 lacks large human trials is probably more mundane: it is hard to study, difficult to standardize across compounding pharmacies, and the early-stage evidence has not yet reached the threshold that triggers major research investment. That is different from suppression.
The suggestion to "beware" of physicians who cite insufficient data is actively harmful framing. Asking for human evidence before recommending an unapproved injectable compound is not intellectual cowardice. It is the job.
What should you actually know?
BPC-157 is not FDA-approved, not for any indication. Compounded versions vary in purity and concentration depending on the pharmacy. There is no established safe dose in humans, no long-term human safety data, and no published clinical trial confirming any of the cardiovascular effects described in this video. Subcutaneous injection of a compound without that data carries real, if poorly characterized, risks.
That does not mean BPC-157 is necessarily dangerous or that interest in it is irrational. The preclinical signal is interesting enough that researchers are paying attention. But "interesting preclinical signal" and "ready for clinical use" are separated by years of research that has not been done yet. Anyone considering this compound should be having that conversation with a licensed provider who can weigh their individual health profile, not drawing their protocol from Instagram.
- No human RCTs for BPC-157 cardiovascular effects have been published as of 2024.
- Compounded peptides are not equivalent to pharmaceutical-grade research compounds used in animal studies.
- FDA non-approval does not equal suppression. It means the evidence bar has not been cleared.